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ABSTRACT
The effects of magnesium (Mg^*) supplementation on performance and recovery were 
examined. Initial Mgr' status as well as effects of Mg^* supplementation on plasma Mg^* were 
determined using the sensitive and recently advanced measure of ionic Mg^' (iMg). The effects 
of initial Mg^' status on these parameters were also studied. Physically active females (n = 121) 
were screened for [iMg] in plasma, and according to the criteria set by Altura, Shirey et al. 
(1994), 36.4% were marginally deficient in the mineral. Thirty-two subjects (21+3 years) 
representing a broad range of [iMg] (0.54 ±  0.04 mmol/L) completed the main 14-week study.
At baseline, participants submitted to a resting blood pressure measurement, and they completed 
both an anaerobic treadmill test and an incremental (aerobic) treadmill test. For the latter, values 
for workload, oxygen uptake and heart rate were obtained for anaerobic threshold and maximal 
effort. Blood samples for iMg, iCa, K \  Na*, Hb, Hct, lactate, and glucose were also collected 
pre-incremental treadmill test, and 4, 10,30 min, and 24 hr post-test. Subjects received 212 
mg/day Mg oxide supplement or matching placebo for four weeks in a double-blind fashion and 
were then retested. Following a 6-week washout period, the testing was repeated with a 
treatment crossover. Magnesium treatment significantly improved resting [iMg] levels in plasma 
but not performance or recovery from exercise. Initial Mg^' status had no effect on these 
parameters. Higher than normal dietary intakes of Mg^* and the relatively low dosage of the 
mineral may have contributed to the absence of treatment effect. In addition, it appears that the 
[iMg] measure is more sensitive than [TMg] or [EMg] warranting the use o f this assay to assess 
the effects of Mg^* treatment in athletic situations. Although not the focus o f the study, it was 
indicated that [iMg] values were somewhat variable within individuals. This effect must be
ii
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CHAPTER ONE: INTRODUCTION
1.1 PURPOSE
The purpose of this investigation was to examine the following with regards to physically 
active females: (1) The effects o f magnesium (Mg^*) supplementation on Mg^~ levels, (2) the 
effects o f Mg^~ supplementation on performance and recovery, and (3) the degree to which 
initial Mg^' status affects the above. This was achieved by utilizing the highly specific, sensitive 
and recently advanced measure o f ionic Mg^* (iMg) assay, and by employing a randomized, 
double-blind, placebo-controlled crossover experimental design.
1.2 IMPORTANCE OF THE STUDY
Many North Americans fail to consume dietary Mg^~ in amounts consistent with 
recommended intakes (Altura, 1994; National Research Council o f Canada [NRCC], 1979).' 
Increased use o f Mgf'-lacking fertilizers in the soil as well as increased refinement of foods has 
steadily reduced the amount o f Mg^' available in many foods grown or processed in North 
America (NRCC). Dietary intakes of normal populations (McDonald and Keen, 1988) as well as 
athletes (Seelig, 1994) have shown that up to half consume diets containing less than the United 
States Recommended Dietary Allowance (RDA) estimated for sedentary adults. Athletes in 
particular tend to have increased needs for Mg^' most likely due to greater urinary and surface 
losses during periods of exercise training (Bohmer, 1995; Deuster, Dolev, Kyle, Anderson and
' Recommended intakes are 200 and 250 mg/day for adult females and males, 
respectively, in Canada (Health and Welfare Canada, 1990), and 280 and 350 mg/day, 
respectively, in the United States (Food and Nutrition Board, National Research Council, 1989).
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Schoomaker, 1987; Resina et al., 1995; Rose, Carrol, Lowe, Peterson and Cooper, 1970). In 
addition, lower intakes and, thus, marginal Mg^' deficiencies are more likely to be found in 
females rather than males (Bohmer, 1994; Faber and Spinnler-Benade, 1991; Lukaski, 1995a).
While it may be assumed that a suboptimal intake o f Mg^* could result in physiological 
impairments, research to date has been equivocal (Lukaski, 1995a) and has relied on insensitive 
indicators ofM gf' status (Elin, 1991-92). Blood biochemical indices in the serum (consisting of 
protein-bound, complexed, and ionic Mg^^) and erythrocytes are not negatively impacted until a 
very severe state of Mg^' deprivation or if a preexisting pathology exists (Elin; Holm, Jepsen, 
Sjogaard and Hessov, 1987; Lukaski). A more sensitive, specific and physiologically meaningful 
indicator of Mg^' status is now available with determinations o f ionized (or free) Mg^' (iMg) 
(Altura, 1994; Altura and Altura, 1994; Altura, Bertschat, Jeremias, Ising and Altura, 1994; 
Altura, Burack et al., 1994; Altura, Shirey et al., 1994; Fogh-Andersen and Siggaard-Andersen, 
1994; Lewenstam (1994); Lewenstam, Blomqvist and Ost, 1994; Maj-Zurawska, 1994; Marsoner 
et al., 1994; Shirey, 1995). With this new technology one can assess whether a subclinical Mg^' 
deficiency does exist and thereby allow a clearer examination of the effects of Mg^" 
supplementation.
This study is important in providing evidence of whether Mg^" supplementation is of 
value for physically active women. Athletes, coaches, health professionals (doctors, exercise 
physiologists and nutritionists), food production industries, and nutritional supplement 
companies would all have a vested interest in the findings. Not only is performance 
enhancement advantageous but adequate recovery is also important for athletes so that they are 
less susceptible to overtraining and thus are more likely to improve their performance and
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
health. In sport, it is increasingly necessary to find out every way possible to improve 
performance as well as to remain healthy in the process. This study also adds to the limited data 
on reference values for [iMg] in the physically active female population.
1.3 DEFINITIONS
(1) Overtraining - condition in which there is an imbalance between exercise and recovery 
resulting in severe and prolonged fatigue (Kuipers and Keizer, 1988)
(2) Physically Active - performing at least three workouts per week for at least two hours total at 
an intensity o f at least 75% o f maximum effort
(3) Recovery - the process o f reestablishing homeostasis within the muscle
(4) Subclinical Magnesium Deficiency - [iMg] of less than 0.53 mmol/L with no apparent 
clinical symptoms (Altura, Shirey et al., 1994)
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1.4 ABBREVIATIONS
ADP - Adenosine Diphosphate
ANOVA - Analysis of Variance
ATP - Adenosine Triphosphate
Ca:- - Calcium Ion
DBP - Diastolic Blood Pressure
DNA - Deoxyribose Nucleic Acid
DOMS - Delayed Onset Muscle Soreness




iCa - Ionic Calcium
iMg - Ionic Magnesium
K ' - Potassium Ion
MBC - Mononuclear Blood Cell
M - Magnesium-treated
Mg - Magnesium
m J* - Magnesium Ion
Mg^'-ATP - Magnesium-Adenosine Triphosphate
M/P - Magnesium-treated First / Placebo-treated Second
Na" - Sodium Ion
P - Placebo-treated
P/M - Placebo-treated First / Magnesium-treated Second
RBC - Red Blood Cell
RDA - Recommended Daily Allowance
RNA - Ribose Nucleic Acid
RNI - Recommended Nutrient Intake
SBP - Systolic Blood Pressure
T1 - First Testing Session
T2 - Second Testing Session
T3 - Third Testing Session
T4 - Fourth Testing Session
TMg - Total Serum Magnesium
2,3-DPG - 2,3-Diphosphoglycerate
Ve - Ventilation
Vgpeak - Peak Ventilation
VO2 - Volume of Oxygen Uptake
VO^max - Maximum Volume of Oxygen Uptake
WBC -White Blood Cell
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1.5 LIMITATIONS
(1) Ionic Mg^' levels were indicated to have some degree o f variability within individuals. The 
reasons for this variability are unclear but this factor limited the ability to accurately diagnose 
Mg^* deficiencies and classify subjects based on iMg status.
(2) The reference values for [iMg] are not well established, especially for the physically active.
(3) The analyses of the hematological parameters were dependent upon the accuracy of the Stat 
Profile™ Ultra Analyzer® model 11-3C (Nova Biomedical Canada Ltd., Mississauga, ON).
(4) The analyses of the dietary intakes were dependent upon the accuracy of the information 
recorded by each athlete, on whether the three days analyzed represented true usual intakes, on 
the accuracy and consistency of the investigators’ interpretations, and on the accuracy of the 
software Diet Analysis Plus™ ©1996 by West Publishing Co., St. Paul, MN.
(5) The recording of objective and subjective measures in the training diary were dependent 
upon the accuracy and consistency of the information recorded by each athlete.
(6) The analyses of expired gases were restricted to the accuracy of the SensorMedics Vmax 
System® metabolic cart ©1996 (Yorba Linda, CA).
(7) The analyses of the maximal parameters for the treadmill tests were restricted to the 
subjects’ motivation to reach their potential.
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1.6 DELIMITATIONS
(1) Participants included 32 apparently healthy and physically active females who ranged in age 
from 17 to 29 years of age and who all resided in Thunder Bay, Ontario, Canada during the study 
period.
(2) Screening included [iMg] levels.
(3) Hematological assays included [iMg], [iCa], [Na*], [K*], [Hb], Hct, [plasma lactate] and 
[plasma glucose].
(4) Dietary analyses were conducted for three days each at both T1 and T3.
(5) Self-reported variables in the training log included length o f workout(s), length of sleep, 
training willingness, appetite, irritability, muscle soreness, minor illnesses and injuries, 
gastrointestinal (Gl) difficulties, menstrual irregularities, and stressful events.
(6) Anthropometric, health and exercise performance tests included weight, height, five skinfold 
measures, blood pressure, and incremental (aerobic) and anaerobic treadmill tests. Aerobic 
versus anaerobic athletes were not distinguished, thus, these groups were not compared. It has 
been suggested that the more anaerobic the exercise, the more Mg^" is lost in the urine (Deuster 
etal, 1987).
(7) Only 212 mg elemental Mg^’ per day dosage amount in the form Mg oxide was administered 
as supplementation.
(8) Only 4-week treatment periods were utilized with a 6-week washout period between.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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CHAPTER TWO: REVIEW OF LITERATURE
2.1 INTRODUCTION
The purpose of this chapter is to first review the roles of Mg^* in the body in order to 
show how Mg^' status can affect exercise performance and recovery measures. Secondly, intakes 
of Mg^~ are reviewed for their effectiveness in achieving adequate Mg^* stores. Thirdly, the 
techniques for assessing Mg^' stores are compared with one another. Next, the causes and effects 
of Mg^" deficiency are discussed in order to emphasize the need for measuring Mg^' status and 
for maintaining sufficient stores o f the mineral. All o f these concepts then form the basis for 
discussing the various studies dealing with measures of Mg^* status and/or Mg^" supplementation 
and their relation to indices of exercise performance and recovery.
2.2 PHYSIOLOGICAL ROLES OF MAGNESIUM
Magnesium is an essential mineral and is a cofactor for over 325 enzymatic reactions 
involved in cellular energy production and storage, protein synthesis, deoxyribose nucleic acid 
(DNA) and ribose nucleic acid (RNA) synthesis, cell growth and reproduction, adenylate cyclase 
synthesis, maintenance o f cellular electrolyte composition, and stabilization of mitochondrial 
membranes. The physiological consequences of these biochemical activities include Mg^*’s 
central roles in the control o f neuronal activity, cardiac excitability, neuromuscular transmission, 
muscular contraction, vasomotor tone, and blood pressure. (Altura, Shirey et al., 1994). The 
intracellular functions o f Mg^* are achieved through the formation o f magnesium adenosine 
triphosphate (Mgr'-AT?) - a substrate for a wide variety of enzymes (e.g., phosphatases and
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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phosphokinases) located in cell membranes or intracellular compartments (Al-Ghamdi, Cameron 
and Sutton, 1994).
As a cofactor to enzymes that require ATP, Mg^* exercises control over electrolyte 
balance across cell membranes. Conduction is a function of an electrical gradient across a nerve 
or a muscle cell membrane. The sodium-potassium (Na^'-K*) pump which is ATP-dependent 
establishes this electrical gradient by pumping ionized K* into the cell. The contraction 
mechanism of any muscle tissue (cardiac, smooth and skeletal) depends on extracellular calcium 
(Ca^"). Similar to the Na^'-K* pump, there is a Mg^'-ATP pump that forces ionized Ca^' (iCa) out 
of the cell. As a muscle cell depolarizes, iCa rushes in and binds to troponin which results in 
rotation o f the troponin-tropomyosin complex, thereby exposing the myosin binding sites on 
actin and the subsequent binding of myosin to actin. The actin-myosin crossbridge formations 
are the basis of a muscle’s contraction. Magnesiiun also serves as a Ca^'-channel blocker to 
modulate cardiac, vascular and skeletal muscle contraction. If an individual has too little Mg^", 
then too much Ca^' is admitted into the cell. Too much contraction leads to hypertension, 
tachycardia, neuromuscular irritability and muscle cramps. Conversely if one has too much Mg^" 
in the cell, then too little Ca^' is being admitted and too little contraction results leading to 
hypotension and bradycardia (Shirey, 1995).
The role which Mg^' plays in controlling cell membrane permeability also relates to its 
speculated role in preventing delayed onset muscle soreness (DOMS) after a bout of 
unaccustomed exercise. Alterations in cell membrane permeability results in a significant 
increase in Ca^" influx from the extracellular fluid to the muscle fibres. The Ca^" ions activate a 
Ca^'-dependent proteolytic enzyme responsible for selective degradation of Z-lines, troponin and
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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tropomyosin. Progressive deterioration would then permit diffusion of the intracellular 
components into the plasma. This would then induce chemotactic activity by white blood cells 
(WBCs) which would be converted into macrophages and activate mast cell degranulation in the 
areas o f damage (Dragani, Giamberardino and Vecchiet, 1994).
Magnesium is necessary for the transfer, storage and utilization of energy. Intracellular 
Mg^' activates entymes in the breakdown of fatty acids, amino acids and glucose during energy 
metabolism. The intracellular [iMg] serves to regulate intermediary metabolism through the 
activation of rate limiting enzymes such as creatine kinase, hexokinase, pyruvate dehydrogenase 
and enolase (Altura, 1991-92).
Magnesium controls hemoglobin (Hb) function since most of the ATP in red blood cells 
(RBCs) is bound to the mineral in the Mg^'-ATP complex (Buim, Ransil and Chao, 1971). There 
is also evidence that the synthesis of erythrocyte 2,3-diphosphoglycerate (2,3-DPG) is Mg^*- 
dependent (McDonald and Keen, 1988; Resina et al., 1994) through the activation of hexokinase 
(Casoni et al., 1990). Thus Mg^’ may control Hb’s oxygen delivery to the working muscles 
(Resina et al., 1994; 1995). It seems that the maintenance of an adequate Mg^* status is of utmost 
importance for efficient delivery of oxygen for rapid energy release so that performance is 
optimal. The mineral also plays a vital role in regulating cell growth, reproduction and 
membrane structure, by regulating DNA and RNA synthesis and structure (Altura, 1991-92).
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
10
2.3 INTAKE OF MAGNESIUM
2.3.1 Absorption and Excretion o f Magnesium
Normal absorption is dependent upon total Mg^' intake, intestinal transit time, and the 
absorption rate o f water (Health and Welfare Canada [HWC], 1990). Absorption o f Mg^' 
through the jejunum and ileum is reported to be in the 40 to 50% range in normal dietary 
conditions (Elin, 1991-92). However, with increasing intakes, absorption has been shown to 
increase whereas fractional absorption has been shown to decrease, ranging from a fractional 
absorption of 65% at the lowest intake (a standard meal with no supplemental Mg^*) to 11% at 
the highest intake (a standard meal with 40 mmol Mg acetate added) (Fine, Santa Ana, Porter 
and Fordtran, 1991). In conditions o f extremely low intakes, the kidney can conserve all but 12 
mg o f Mg^' per day (HWC, 1990).
Urinary Mg^* excretion has been correlated with Mg^' intake and has shown to have 
increased significantly with supplementation (Borella, Bargellini and Ambrosini, 1994).
Spencer, Fuller, Norris and Williams (1994) studied five male subjects who exhibited an 
increase in absorption with 800 mg/day intake as compared to that noted with their normal 
intakes which were below the RDA of 350 mg/day. These subjects showed increases in both 
urinary and fecal Mg^" excretion but were also able to develop a positive Mg^' balance through 
supplementation.
Although bone and the Gl tract play a part in Mg^" homeostasis, the kidney is the prime 
regulator of Mg^' balance (HWC, 1990). In the kidney, normally 3 to 6% of the filtered load is 
excreted (Altura, 1991-92). Approximately 25% of the filtered Mg^" is reabsorbed in the 
proximal tubule while 50 to 60% is reabsorbed in the ascending loop o f Henle.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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2.3.2 Dietary and Supplemental Intakes
Lukaski ( 1995b) mentions that the best way to achieve an adequate Mg^* intake is 
through a balanced diet if at all possible. Some good dietary sources of Mg^' are found in whole 
grains, raw nuts, milk, seafood, bananas, potatoes, seeds and leafy green vegetables. Some 
examples of foods with high Mg^' content are spinach ( 1 cup cooked = 150 mg), beans and 
black-eyed peas ( 1 cup cooked = 70-100 mg), and tofu (0.5 cup = 125 mg).
Lukaski (1995b) goes on to review that excessive fibre intake may decrease Mg^* 
absorption since Mg^" binds to fibre resulting in its rapid transit through the GI tract. Typical 
western diets which are high in protein and/or fat do not seem to harm Mg^* absorption or 
excretion, although these diets may not contain sufficient amounts of the mineral. Increases of 
both dietary Ca^" and phosphate do not adversely affect Mg^* balance. If an individual is not able 
to acquire sufficient Mg^’ from their diet, Mg^' supplementation may be beneficial.
Supplemental Mg^" may be taken as gelatin capsules or tablets with Mg^* salts. In general, Mg^" 
salts have a fractional absorption of about 20%. Most Mg^* supplements which are available to 
the public are combined with other minerals such as Ca^', K*, phosphorus, and zinc, and/or with 
vitamins such as D and B-6. This suggests that Mgf' supplementation may be widespread.
2.4 ASSESSMENT OF MAGNESIUM STATUS
2.4.1 Distribution o f Magnesium
Magnesium is second only to K ' in intracellular composition and it resembles K* in 
distribution about the body (Altura, 1991-92). Magnesium amounts to about 21 to 28 g (or about 
1% of the mineral content) in the average adult man (Altura; Elin, 1991-92), and is the fourth
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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most abundant macromineral in the human body. Sixty percent o f  it is stored, and is relatively 
unexchangeable, in bone along with Ca^" and phosphorus, and about 20 to 27% is found in 
skeletal muscle (Altura; Elin). Less than 1% of the total body Mg^* exists in blood, and about
0.3% is present in the blood serum (Elin). The cells o f the body contain about 38% of Mg^* 
whereas the extracellular fluid contains only 1 to 2%. There is still much uncertainty as to the 
exact proportions of Mg^' distribution in the body, and only recently have measures been made 
for [iMg] in the serum and in whole blood. The preliminary data show that [iMg] comprises 
about 71% of [TMg] in serum (Altura, 1991-92). The remainder o f the TMg is bound to 
nonspecific proteins or is complexed.
2.4.2 Tissue Magnesium
There are two tissues which have been primarily used for clinical medicine - blood and 
muscle. Within the blood, assays can be derived from serum, RBCs and mononuclear blood cells 
(MBCs), while the muscle measure can be obtained from a biopsy. The combination of all of 
these measurements usually represents the total Mg^* content of the body, and that one measure 
does not necessarily relate to another (Elin, 1991-92). Al-Ghamdi et al. (1994) report that the 
[TMg] is maintained within a narrow range by the kidney and small intestine. In Mg^* depletion, 
both organs increase the absorption of Mg^". If further depletion occurs, bone stores give up 
Mg^* to the plasma. Thus [TMg] can be normal in the presence o f Mg^' deficiency. If the 
depletion is severe enough the result is Mg^" deficiency. The reference interval for [TMg] in 
human adults is 0.75-0.96 mmol/L (Elin, 1991-92). Values below this range are considered to be 
Mg^'-deficient. Borella et al. (1994) found that only subjects with the lowest Mg^* intake had
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lower values o f [TMg]. Similarly for [EMg], Borella and colleagues discovered a 10% lower 
value in marginally deficient subjects as compared to controls. Elin ( 1991-92) reports that a 
fairly new test for assessing Mg^' status is the determination of Mg^' in MBCs which is taken 
from the leucocytes in blood. Magnesium levels in MBCs have not correlated highly with [TMg] 
or [EMg] and additional studies will need to ascertain the correlation between MBCs and muscle 
tissue. The biopsy method of measuring muscle indices is tedious and costly and uncomfortable 
for subjects therefore this measure is left out of most studies in this area.
The majority of studies to date have measured [TMg], however, [iMg] is the most 
important fraction of the measure since it is the physiologically active portion (Elin, 1991-92). 
This portion o f Mg^* serves to regulate metabolism through activation of rate-limiting enzymes 
such as hexokinase, pyruvate dehydrogenase, enolase and creatine kinase (Altura, 1991-92). 
Moreover, the method of measuring [iMg] has recently become more available to perform. This 
measure can be determined by the use of an electrode in which iMg is separated out of the serum 
in a blood sample. Newer ion-sensitive electrodes have been designed to function in the 
presence of iCa and other potential cationic interferences found in the blood o f normal and 
diseased human subjects and animals. The speed o f determining [iMg] with these ion-sensitive 
electrodes has aided the clinical application of the [iMg] measure to numerous conditions. Some 
of these syndromes include diabetes, cardiopulmonary bypass, organ transplantation, neonatal 
distress, migraine headaches, atherogenesis and hypertension (Altura, 1994). Plasma iMg can be 
determined using a plasma, serum or whole blood sample. Ionized Mgf' appears to cross the cell 
membrane relatively quickly which would suggest that the two reservoirs are in dynamic 
equilibrium (Shirey, 1995). This has important implications when trying to assess whole body
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Mg^’ status, since, as stated previously, [TMg] measurements are not reflective o f intracellular 
concentrations. For a more thorough review of iMg sensitive electrodes and their clinical 
applications, the reader is referred to the Scandinavian Journal of Clinical and Laboratory 
Investigation, Vol. 54, Suppl. 217, 1994.
2.4.3 Physiological Assessment ofM agyiesitm Status
Elin (1991-92) reports four other tests for the physiological assessment o f Mg^* status,
i.e., those requiring Mg^* to be metabolized during testing - balance studies, renal excretion 
studies, isotope studies, and retention o f Mg^* following acute administration of isotopes. These 
measures all require normal absorption, tissue uptake and excretion rates for proper accuracy. 
Balance studies are very costly and are not available for routine assessment o f Mg^* status but 
would provide important questions about Mg^* metabolism. Renal excretion measures often 
involve a 24-hour period of urine collection. Excretion studies depend on intake, absorption and 
renal function and, thus, can detect any failures in renal function. Under normal circumstances 
Elin mentions that daily excretion rates of Mg^' are in the range of 3.6 + 1.4 mmol for females 
and 4.8 + 1.5 mmol Mg^* for males. Isotope studies are used for clinical research. They involve 
injecting a Mg^* isotope into the antecubital vein and measuring excretion (and thus retention) 
rates in the urine for 24 to 48 hours (Holm et al., 1987). Following the parenteral administration 
of a Mg^" load, the retention rate can be measured and this has recently become a very valuable 
tool in Mgf^ status assessment. Magnesium deficiencies are said to be indicated if  retention is 
higher than 40% in a 24-hour period (Hinds, Bell, McMaster and McCluskey, 1994). Holm and 
coworkers (1987) suggest that since there exists a relation between the concentration of Mg^* in
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muscle and Mg^* retention, the Mg^~ load test could be used to diagnose even marginal Mĝ * 
deficiencies. The test is also much easier and less costly that the muscle biopsy procedure.
Lastly, the retention o f Mg^' following acute administration of a Mg^* load is becoming more 
popular in diagnosing deficiencies. If the amount o f the load, the length of time to infuse the 
load, and the length o f time for urine collection becomes standardized, this test will have high 
clinical value in detecting deficiencies (Elin, 1991-92).
2.4.4 Simmary
Research in Mg^~ status has been unclear and has been hampered in part by the lack of an 
accurate and sensitive indicator of Mg^~ status and deficiency (Elin, 1991-92; Holm et al., 1987; 
Lukaski, 1995a). It seems that the hematological indices of [TMg] and [EMg] are not negatively 
impacted until a very severe state o f Mg^' deprivation. Thus any deficiencies would not be 
discovered early enough by using only these indices. It is evident that the utilization of [iMg] 
and/or physiological tests for assessing the body’s Mg^' is in order for studies in sports medicine.
2.5 MAGNESIUM DEFICIENCY
2.5.1 Causes o f Magnesium Deficiency
Hypomagnesemia can arise from inadequate intakes of the mineral but severe 
deficiencies of the mineral are rare because of the remarkable ability of the kidney to conserve 
Mg^*. The condition may also result from malabsorption due to various disorders of the G1 tract 
(Al-Ghamdi et al., 1994), renal dysfunction, bums, diabetic keto-acidosis, alcoholism, long-term 
diuretic use, hyperparathyroidism and cirrhosis (HWC, 1990; Kreg and Murray, 1986). By far
I
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the most important cause of clinical hypomagnesemia is from excessive loss through severe and 
prolonged diarrhea (Zilva and Pannall, 1979). Genetic differences in Mg^* utilization may also 
be a factor in accounting for differences in stress reactions and in vulnerability to Mg^* 
deficiency. It is also evident that intense prolonged physical exercise can cause Mg^~ deficiency 
(Lijnen etal., 1988; Rose et al., 1970; Stendig-Lindberg, 1991)
The daily intake of Mg^~ has been declining steadily in North America since the turn of 
the century. Due to the increasing use of fertilizers (lacking Mg^*) and food processing 
(removing Mg^O in practice today, intakes have declined from 500 mg/day to about 175 to 225 
mg/day (Altura, 1994; NRCC, 1979). Daily intakes of Mg^' can be evaluated from self-report 
dietary records. As values from 70 to 100% of the RDA are considered adequate for an 
individual, cause for concern results when intakes are less than 70% of the RDA (Lukaski, 
1995a). Well over 50% of the normal population have Mg^* intakes below that of the RDA 
which is in the range of 280-350 mg/day depending on sex, age and condition (McDonald and 
Keen, 1988). Severe Mg^" deficiency, however, is rare in developed countries because of the 
increased availability of most foods (Seelig, 1994).
Clarkson and Haymes (1995) indicate that athletes appear to have adequate Mg^* status, 
however, those who are on calorie-restricted diets may not be obtaining sufficient Mg^' supply. 
Lukaski (1995b) claims that based on population surveys and data from dietary histories, some 
athletes show intakes which are less than 70% that o f the RDA. Seelig (1994) claims that as 
many as half o f the athletes she has studied consume diets containing less than 50% of the RDA 
for Mg^". Lukaski (1995b) reports that in general, Mg^  ̂intakes for male athletes equal or exceed 
the RDA of 350 mg/day as compared to females who reveal intakes of about 60 to 65% of the
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RDA of 280 mg/day. It has been shown that female field athletes (Faber and Spinnler-Benade, 
1991), bodybuilders (Kleiner, Bazzarre and Ainsworth, 1994), and cross-country runners (Powell 
and Tucker, 1991 ) exhibit dietary Mg^‘ below RDA levels which did not hold the same for their 
male counterparts. Newhouse, Clement and Lai (1993) could not corroborate these findings as 
the mean Mgr' intake o f the recreational level female athletes whom they studied was 342 ±  83 
mg/day. No subjects failed to meet the Canadian Recommended Nutrient Intake (RNI) of 200 
mg/day. Singh, Deuster, Day and Moser-Veillon (1990) actually discovered a higher Mg^' intake 
in highly-trained athletes than untrained ones. Deuster et al. (1986) also found intakes above the 
RDA (i.e., 410 mg/day) in 51 highly-trained female runners. Thus it seems that intakes are 
highly variable indicating that individualized assessment is required. Also, since recommended 
intakes are based on non-athletic populations, and the literature regarding the actual Mg^" status 
of athletes is limited, one can still question whether the observed dietary intakes are sufficient 
for the amount o f energy that the athletes are expending and the potential increased Mg^" losses.
It is evident that further investigations should be conducted in this area.
In an athletic population, increased Mg^* loss usually occurs through urine, sometimes 
through sweat (Rose et al., 1970), or through feces due to diarrhea (Al-Ghamdi et al., 1994; 
Spencer et al., 1994; Zilva and Pannall, 1979). The amount lost through urine has been found to 
increase on exercising vs. control days and with the degree o f anaerobic activity (Deuster et al., 
1987). These authors also found that urinary loss returns to normal the day after exercise. 
However, repeated bouts of exercise which do not allow a day to recover may result in 
accumulated Mg^* loss and perhaps an eventual deficiency. Indeed, Resina et al. (1995) found 
that one month of daily endurance training led to significant decreases in Mg^' stores through
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urinary losses causing a marginal Mg^' deficiency. On the other hand, urinary Mg^' excretion did 
not differ for highly-trained vs. untrained female runners according to a study done by Singh and 
colleagues (1990). Hypoxia may be the mechanism behind a urinary Mg^' loss. Hypoxia results 
in the breakdown o f ATP causing the release o f iMg into the cytosol and then into the plasma. 
Ionized Mg^* is subsequently lost at the kidneys. The resynthesis of ATP during reperfusion 
would reverse the flow of iMg back into the cell leaving a plasma deficit (Shirey, 1995). This 
model also explains the Mg^* loss that has been observed following cardiopulmonary bypass 
surgery and the redistribution o f Mg^* immediately after exercise (to be discussed later).
Controversial data thus exists regarding the possibility of intense endurance exercise 
decreasing the Mg^" balance. An inadequate dietary intake coupled with potential increased 
losses could certainly put the athlete at risk of deficiency.
2.5.2 Effects o f Magnesium Deficiency
As stated previously, Mg^" is involved in the control of neuronal activity, neuromuscular 
transmission, muscular contraction, cardiac excitability, vasomotor tone, blood pressure and 
peripheral blood flow (Altura, 1991-92). Since Mg^~ plays such a vital role in so many 
physiological activities, a deficiency of the mineral can cause many negative consequences for 
an individual. Hypomagnesemia could present itself through a wide range of clinical features as 
depicted in Table 1.
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Most hypomagnesemia in clinical practice is asymptomatic with the signs and symptoms 
becoming evident once [TMg] drops below 0.5 mmol/L (Al-Ghamdi et al., 1994). This is not to 
say that milder cases of hypomagnesemia are not without consequence, but rather [TMg] 
determinations have not routinely been determined to establish the mineral’s association with 
various disorders. To correct this situation, Al-Ghamdi and co-workers suggest that [TMg] be 
routinely ordered in all acute care units and in all patients with conditions or medications that 
may predispose them to Mg^~ deficiency. Taking the suggestion one step further, [iMg] 
determinations could add more sensitivity to Mg^' status changes.
Altura and coworkers have been pioneering the research linking more subtle degrees of 
hypomagnesemia to a variety o f pathological syndromes. With the utilization of [iMg] measures, 
they have shown that a chronic deficiency of Mg^' is associated with atherogenesis, 
hypertension, type II diabetes, eclampsia, migraine, headaches, decreased resistance to 
endotoxins, cardiac arrhythmias, asthma and complications from cardiac surgery. The clinical 
course for some of these disorders is correlated with [iMg] and not [TMg] (Altura, Shirey et al.,
1994).
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
20
The effects o f hypomagnesemia on athletic performance are quite speculative due to 
problems involving the precise determination o f Mg^" status in athletes, the confounding effects 
that exercise might have on the redistribution of Mg^*, and the equivocal studies to date on the 
beneficial effects of Mg^' supplementation. These topics will now be reviewed.
2.6 MAGNESIUM AND EXERCISE
2.6.1 Magnesium Status in Athletes
Many studies involving exercise performance and recovery do not include any 
measurements o f Mg^* status. In addition, for those studies that do, the precise determination of 
Mg^" status in athletes has been lacking insofar as normal blood indices are usually used to 
assess whole body nutriture. McDonald and Keen (1988) mention that there is growing evidence 
that exercise causes a decrease in the blood indices o f Mg^', and that marginal deficiencies may 
be common among endurance athletes (whose dietary intakes of Mg^' are inadequate). The 
reference interval for normal [TMg] in adults is from 0.75-0.96 mmol/L (Elin, 1991-92). Resina 
et al. (1994) noted that in their sample o f 20 well-trained middle-distance and long-distance 
runners, the mean [TMg] at baseline was 0.786 ±  0.08 mmol/L with 25% of the athletes having 
values representing marginal deficiencies. A one-month period of training did not change the 
mean values although hypomagnesemia was noted in 40% of the post-test sample. It has also 
been found that 111 mostly moderately-trained females had a mean [TMg] value of 0.79 mmol/L 
with 14 subjects (12.6%) having values below 0.73 mmol/L (unpublished raw data from 
Newhouse et al., 1993).
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2.6.2 Acute Effects o f Exercise on Magnesium Distribution
There is typically a fall in [TMg] after intense exercise (Rayssiguier, Guezennec and 
Durlach, 1990). Stendig-Lindberg (1991) claimed that low [TMg] is a significant factor in 
lowering maximum voluntary contraction thus the lowering o f [TMg] signifies that strenuous 
exercise induces Mgr* deficiency. Rose and coworkers (1970) postulated that an observed TMg 
loss was due to sweat after a marathon race. However, more recent studies indicate that 
decreases in [TMg] are more likely due to the redistribution o f Mg^~ from the plasma to the 
RBCs for working muscles to utilize the Mg^* for energy processes (Al-Ghamdi et al., 1994; 
Casoni et al., 1990; Costill, Cote and Fink, 1976). This redistribution is apparently short-lived as 
studies have found that [TMg] usually returns to pre-exercise values within two hours after 
exercise (Deuster et al., 1987; Lijnen, 1995; Lukaski, 1995a). Yet other studies reveal that the 
Mg^* shift is from the plasma to other tissue compartments other than the RBCs (Resina et al.,
1995). Lijnen and coworkers (1988) suggest that adipose cells uptake the Mg^* in these 
situations. Dressendorfer, Wade, Keen and Scaff (1982) studied subjects during a 20-day road 
race: Pre-race [TMg] levels were marginally low, yet commencing on day 2, [TMg] levels were 
significantly higher and remained that way. Magnesium intake was not controlled in this study 
and thus it is postulated that a greater Mg^' intake likely caused the higher [TMg] levels during 
the race. Golf, Happel, Graef and Seim (1984) found that after ergometer exercise, [TMg] was 
unchanged and rather [EMg] had decreased significantly. It is evident from these conflicting 
results that much remains to be done to clarify the compartmental shifts of Mg^* during exercise 
and this can be done by utilizing more of the various aforementioned assays for Mg^* status.
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It is evident that studies of exercise’s effect on Mg^* status and distribution are lacking 
due to methodological problems. By the same token it is also difficult to draw conclusions from 
the literature examining the reverse relationship - that being the effect o f Mg^" status or Mg^" 
supplementation on exercise performance and recovery indices. This relationship will now be 
discussed.
2.6.3 Magnesium Supplementation's Effects on Exercise
It is well documented that an optimal Mg^* status will be beneficial for exercise (Brilla 
and Gunter, 1995; Dragani et al., 1995; Ripari, Pieralisi, Giamberardino, Resina and Vecchiet, 
1989; Vecchiet et al., 1995). What can be misleading to some is the myth of which the popular 
press seems to promote, that Mg^* or any other mineral supplementation can improve one’s 
health no matter what one’s dietary intake is already (McDonald and Keen, 1988). There are few 
studies which reveal that excessive Mg^* supplementation actually improves performance. It is 
important to remember that if an athlete is to supplement, he or she should be focusing on 
correcting a Mg^* deficiency. Too many athletes are convinced that by merely taking nutritional 
supplements their performance will be enhanced. McDonald and Keen claim that excessive Mg^* 
supplementation is not thought to be a serious problem, yet Al-Ghamdi et al. (1994) show that 
over 500 mg/day supplemental Mg^~ may result in GI difficulties. In one study it was found that 
after 3 months of supplementation of a multivitamin and mineral supplement including 116 mg 
of Mg^*, no change in Mg^* status was indicated (Weight, Noakes et al., 1988), and no ergogenic 
effect was indicated (Weight, Myburgh and Noakes, 1988). Yet these subjects’ Mg^~ statuses 
were reported to be in the normal range throughout the study. On the other hand, Classen et al.
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(1986) claim that many experiments indicate that Mg^' supplementation may benefit 
normomagnesemic subjects. The issue with this statement, again, is that measures o f Mg^* status 
may have been inadequate to detect the presence of Mg^* deficiencies in some subjects 
participating in the investigations.
A prolonged Mgf* deficit may progressively impair athletic performance (Golf, Bohmer 
and Nowacki, 1993). Ripari et al. (1989) found that supplementation with 4.5 g/day Mg pidolate 
(a Mg^" salt) resulted in significantly reduced physiological stress in submaximal exercise. Brilla 
and Gunter (1995) discovered similar results with daily supplementation of 8  mg per kg body 
weight Mg oxide in a crossover study. Golf and co workers summarize that Mg^" 
supplementation can improve performance in many sports either in competition or during 
maximal and submaximal exercise tests. Indeed, without Mg^*’s effective control over energy 
transport pathways to provide sufficient energy supply, peak performance is not possible.
The studies just cited did not include any measures o f Mg^* status which makes it 
uncertain whether the subjects were originally deficient or not. Supplementation has been shown 
to increase performance in athletes with [TMg] at the low end of the normal range. A group of 
male competitive rowers supplemented with 360 mg/day Mg^* for four weeks showed a decrease 
in oxygen consumption at the same submaximal workload (Golf et al., 1993). Some subjects 
with normal [TMg] revealed enhanced maximal volume of oxygen uptake (VOzmax) and 
physical work capacity with supplementation (Steinacker, Grunert-Fuchs, Steininger and 
Wodick, 1987; Vecchiet et al., 1995). This phenomenon is, again, most likely due to an 
intracellular deficiency of Mg^*. These results suggest the potential benefit of Mg^* 
supplementation on energy metabolism and work efficiency for intense endurance exercise.
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The measure of plasma glucose has been found to be decreased during and after intense 
endurance exercise (MacKinnon and Hooper, 1991). Golf and co-workers (1993) review that 
physical stress induces glucose uptake by muscle cells and its oxidation to pyruvate and lactate, 
and therefore is involved in the acceleration of glycolysis. The functions of glucose are insulin- 
dependent, and insulin, in turn, is dependent on Mg^* for it to bind to the cell membrane receptor 
for its activation. Thus, an increase in Mg^* supply will increase insulin responsiveness for 
glucose. Moreover, for glucose to be taken up by muscle cells, hexokinase is needed. This 
en^rnie is also dependent on the presence of Mg^" as previously stated. Seelig (1994) states that 
low Mg^' levels may also aggravate emotional stress which, in turn, further lowers Mg^* levels. 
This subsequently leads to a Mg^T-stress cycle whereby the more stressed one gets the more Mg^' 
is excreted from the body. Thus, stress (whether physical or mental) increases the need for Mĝ *.
Golf and colleagues (1993) review that Mg^* also affects lactate metabolism after 
exercise. They reported that after competitive swimming and rowing, a concurrent accelerated 
lactate elimination from blood was observed after Mg^~ treatment. Seeing as lactate 
concentration in plasma represents the extent of acidosis and the stress of the lactic acid system 
during physical stress, lowered post-exercise lactate levels are said to be indicative of improved 
recovery.
An adverse effect o f some exercise is Delayed Onset Muscle Soreness (DOMS) which is 
a complex of muscle soreness symptoms (Dragani et al., 1995). The symptoms begin about 8-10 
hours after exercise, peak at about 24-48 hours, and start to decrease gradually after 3-4 days so 
that 5-7 days post-exercise, they are gone (Armstrong, 1984). Armstrong hypothesized that the 
DOMS symptoms start from the rupture of structural proteins and associated connective tissue in
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muscle fibres. These symptoms are induced by the high mechanical forces developed during the 
physical activity. Dragani et al. (1995) go on to discuss the mechanisms of DOMS and how Mg^* 
is involved in them: Alterations in the cell membrane permeability results in a significant 
increase in Ca^* influx from the extracellular fluid to the muscle fibres. The Ca^* ions 
accumulate in the mitochondria inhibiting cell respiratory functions and resulting in painful 
cramps. An ATP deficit subsequently arises and this makes it more difficult for the ridding of 
Ca "̂. However, Mg^~ is known to favour cellular energy production since it is essential in the 
regulation o f metabolic pathways involving ATP and erythrocyte 2,3-DPG (Resina et al., 1995). 
Therefore, an adequate Mg^' supply serves to effectively counteract the Ca^* influx in the cell at 
the membrane level to decrease symptoms of DOMS. Dragani et al. undertook a study which 
tested the hypothesis that a 3-week intake of 387 mg/day Mg pidolate supplement by non Mg^*- 
deficient subjects would minimize DOMS after eccentric stepping exercises. They found that the 
treatment group experienced lower spontaneously perceived pain on the first day and that it 
decreased rapidly remaining constantly less severe than the values found for the placebo group.
It seems that there is an increased energy available to muscle cells as well as a protective 
effect that goes along with the Mg^' supplementation vs. muscle damage due to exercise. 
Therefore it is proposed that there is a requirement to have additional Mg^* intake to prevent 
muscle damage, and a need for supplementation in periods o f intense exercise. The controversy 
with this hypothesis is that the singular measure o f [TMg] has been inadequate in detecting 
deficiencies. Bohmer (1995) reminds us that Mg^* fluxes from the plasma take time to return to 
pre-exercise values (normally occurring within 24 hours), thus, there must be enough TMg
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supply to combat the repeated exercise bouts inherent in training so that an athlete experiences 
less muscle damage and soreness for improved recovery.
2.7 RECOVERY AND OVERTRAINING VARIABLES
From the literature cited up to this point, it has been indicated that Mg^* supplementation 
may result in increased effectiveness o f recovery from exercise stress. (Recovery is the process 
o f reestablishing homeostasis within the muscle.) The recovery parameters which have already 
been discussed include oxygen consumption, work capacity, and the concentrations of lactate 
and glucose in the blood. Although there is considerable speculation, negative changes in these 
variables are also said to be indicators o f overtraining. Overtraining is the condition in which 
there is an imbalance between exercise and recovery resulting in severe and prolonged fatigue 
(Kuipers and Keizer, 1988). This condition directly involves performance decrements and 
ineffective recovery from exercise. Other indicators o f overtraining are now discussed.
As alluded to earlier when discussing DOMS, persistent muscle soreness is one valid 
indicator of chronic physical exertion in athletes. MacKinnon and Hooper (1991 ) review that an 
elevated resting heart rate also appears to be a strong indicator. Stray-Gundersen, Videman and 
Snell (1986) found that when they purposely overtrained runners for two weeks, resting heart 
rates remained significantly elevated even following another two weeks o f recovery. Systolic 
blood pressure is also a good indicator o f overtraining although it is usually not readily available 
for daily monitoring. However, elevated pulses and blood pressures can stem from other 
stressors in life, from illnesses, or from certain medications, thus caution must be in interpreting 
such data.
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Loss of appetite and unexplained weight loss are often used as signs of overtraining and 
should be measured together. The loss of body weight may be due to a decreased appetite and 
increased resting metabolic rate, both reported to occur with overtraining. Psychological effects 
have also been related to the syndrome and these include increased irritability, lack of 
motivation to exercise, and sleep disturbances. These effects may be due to changes in 
hormones, e.g., cortisol, which is a hormone that is linked to depression.
In addition to all of the markers discussed so far, it has been found that an increased 
incidence o f minor illnesses, GI difficulties, and menstrual irregularities have been linked to 
overtraining (MacKinnon and Hooper, 1991). These effects may be due to altered metabolism 
and hormonal status from exercise, or from other forms of stress. Higher incidences of minor 
injuries may also result from decreased coordination in a fatigued state. Finally, MacKinnon and 
Hooper advise of the importance o f monitoring a wide variety of overtraining and recovery 
markers since subjects hardly ever exhibit every one of the signs and symptoms which have been 
mentioned. Studies have been lacking with respect to Mg^* supplementation’s effects on certain 
markers of recovery and overtraining as recorded in a daily training diary thus further study 
needs to be done in this area.
2.8 SUMMARY
In summary of the literature, it is apparent that some studies show that Mg^* 
supplementation results in increased performance and recovery measures whereas others do not.
It is also noted that most studies involving exercise do not use measures of Mg^" status, or else 
use insensitive measures in testing for Mg^' deficiencies in subjects. A number o f studies have
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shown improvements in exercise performance and recovery, yet Mg^* statuses of the subjects 
involved have been relatively unknown. It is therefore not proven that Mg^* supplementation, 
beyond the maintenance of an adequate dietary intake o f the mineral, is effective in enhancing 
performance and recovery from exercise. In addition, little research has concentrated on 
physically active females who may be at the highest risk for Mg^* deficiency.




After informed consent was obtained (Ethics Advisory Committee, Lakehead 
University), 121 apparently healthy, physically active females between the ages o f 17 and 43 
residing in the Thunder Bay, Ontario, Canada region, were screened for participation based on 
iMg status. Those who qualified to continue with the study were twenty marginally Mg^*- 
deficient subjects and twenty who possessed [iMg] levels in the upper range of normal. The 
normal range for [iMg] is 0.53 - 0.67 mmol/L (Altura, Shirey et al., 1994). Selection criteria for 
subjects included:
(1) Having no clinical history o f proven or suspected hypersensitivity to 
Mg^' supplements.
(2) The expectation and willingness to maintain regular physical activity 
(i.e., performing at least three workouts at or above 75% maximum 
intensity, for at least 2  hr total, per week) throughout the study.
(3) The expectation and willingness to maintain regular dietary intakes 
throughout the study.
(4) Having filled out a questionnaire (refer to Appendix A) and consent 
to participate (refer to Appendix B), and having read the instructions for 
participants (refer to Appendix C).
Exclusion criteria for subjects included:
(1) Not performing the incremental treadmill test at all four test sessions.
(2) Not ingesting at least 75% o f pills given per treatment period (as 
verified by pill count).
(3) Being ill or injured (enough to prevent exercising) for more than one 
week during the treatment periods.
(4) Not maintaining a training load equal to ± 25% o f their regular load.
A power test utilizing previous test data on VO^max values from Brilla and Gunter 
(1995) indicated the sample size of 40 should be sufficient to reach a power of 0.80 in detecting
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
30
an effect size o f 3 ml/kg/min. Enrolment continued until the requisite number of subjects had 




Selected subjects underwent the following tests:
a. Dietaiy analysis:




IV. Skinfolds (sum of five skinfolds; predicted % body fat - Dumin-Womersley 
method)
c. Physiological tests:
V. Resting blood pressure
VI. Incremental treadmill test with measurement of workload, heart rate, and 
expired gases - for assessment ofVOgmax, anaerobic threshold, maximal 
workload, and submaximal running efficiency. Blood was sampled pre-test, and 









Vn. Anaerobic treadmill test (a test o f lactacid capacity performed on a treadmill) 
Vin. Subjective and objective measures o f overtraining to be recorded daily in a 
training diary (refer to Appendix E)
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3.2.2 Te.st Item Protocols
Four testing periods (T l, T2, T3 and T4) were scheduled from October 1996 to February 
1997 with testing taking place at the Human Performance Laboratory at Lakehead University. 
During the weeks of T l and T3, subjects filled out three consecutive days (including one 
weekend day) o f self-report dietary records. Dietary intakes were assessed using computerized 
diet analysis software (Diet Analysis Plus™ ©1996, West Publishing Co., St. Paul, MN). The 
Mg^~ supplements were not included in the analyses. The primary interest of this portion of the 
study was to monitor Mg^" intakes between groups, although macronutrient intake and dietary 
factors that affect Mg^* absorption were also examined.
Subjects were asked to refrain from unaccustomed strenuous exercise for 48 hours (and 
any strenuous exercise 24 hours) prior to exercise testing (and the blood withdrawal associated 
with it). They were also asked to refrain from alcohol consumption 24 hours (and caffeine 
consumption six hours) prior to testing. They were advised to consume a light meal in 
carbohydrate 2-3 hours prior to reporting to the exercise tests which took place between 1 ;00 and 
9:00 p.m. Anthropometric measurements were performed as detailed in the Certified Fitness 
Appraiser Resource Manual [CFARM] (1995) by a Certified Fimess Appraiser. Harpenden 
calipers were used to measure skinfolds which were taken from the triceps, biceps, subscapular, 
iliac crest and medial calf regions. Percent body fat was predicted using the Dumin-Womersley 
method (CFARM).
Resting blood pressure (performed by a Certified Fimess Appraiser using an AMG Med. 
Professional Series sphygmomanometer), and resting heart rate (using a Polar Vantage XL® 
heart rate monitor from Polar CIC Inc.), were obtained after the subject rested in the sitting
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position for 10 minutes. Blood was collected in 7 ml green-topped Vacutainer® tubes (lithium- 
heparin added) by antecubital venipuncture (Pendergraph, 1984). The tourniquet was applied 
gently and released prior to the actual blood draw.
The multi-test Stat Profile™ Ultra Analyzer® model 11-3C (Nova Biomedical Canada 
Ltd., Mississauga, Ontario) was utilized for the immediate analyses of [iMg], [iCa], [N a 'l, [K*], 
[Hb], Hot, [glucose] and [lactate] from 25 of whole blood. The instrument was housed in the 
same laboratory as the exercise testing, and the analyses were performed by the same technician 
throughout the study. The precision of the instrument for [iMg] was estimated at + 0.03 mmol/L, 
as determined by repeat testing, both within and between days, on an individual not involved in 
the study. All analytes were within their respective reference ranges as determined by NOVA 
quality control substances.
Prior to the incremental treadmill test, the subjects warmed up on the treadmill (Quinton 
Instruments, Seattle, WA) for five minutes. The initial treadmill speed was 2.22 m/s (5 mph) and 
was increased by 0.22 m/s (0.5 mph) every minute. The treadmill grade remained horizontal 
until the subject had completed two workloads past the workload at which the subject’s 
respiratory exchange ratio (expired 00% / inspired 0%) passed a value of 1.0. At that time, the 
speed no longer increased but the grade increased by 2 percent each minute. Subjects continued 
until exhaustion. Expired gases were sampled and analyzed by a SensorMedics Vmax System® 
metabolic cart ©1996 (Yorba Linda, CA) with VOjmax and V^peak determined as the highest 
30 second mean. Heart rates were monitored by a telemetric heart rate monitor and recorded 30 
seconds into each workload. Anaerobic thresholds were assessed via examination of expired gas 
values according to the method described by Beaver, Wasserman and Whipp (1986). Two
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investigators blinded to the study, and familiar with anaerobic threshold estimations, 
independently analyzed the V ê coz curves to pick out the lowest point. These researchers then 
met to compare estimates. Discrepancies (more than one minute difference) were resolved by 
examining other expired gas indices o f anaerobic threshold. Efficiency of running at a 
submaximal workload was assessed by noting the workload during the T l test that corresponds 
to 65% o f VOzmax. At T2, T3, and T4, the otygen consumption was noted at this same 
workload.
The anaerobic treadmill test was performed 48 hours after the incremental treadmill test, 
and according to the protocol described by Bouchard, Taylor and Dulac (1982). In brief, the test 
required the subjects to exert a maximal effort on the treadmill with the speed set at 3.31 m/s (7 
mph) and the grade set at 20%. Time to exhaustion (approximately 30 to 90 s) was the only 
variable measured.
Encouragement was given equally to all subjects for all treadmill tests. The protocols 
described above remained identical for each of the four testing periods. The timing in terms of 
day of week and time of day were consistent for each subject with a few exceptions to 
accommodate subjects’ schedules.
3.2.3 Schedule o f Events fo r Testing Sessions
The screening of the 121 subjects for [iMg] (and administration o f consent forms, 
questionnaires and instructions) was conducted over three days in early October. Three weeks 
later, the first testing session (T l) began. Each of the four testing sessions (T l, T2, T3 and T4) 
involved the following: Day One consisted of the distribution o f dietary records (Tl and T3
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only), and submission to anthropometric tests, resting heart rate and blood pressure 
measurement, and an incremental treadmill test with pre-test, and 4, 10, and 30 min post-test 
blood withdrawal. Day Two involved only the 24 hr post-test blood withdrawal. Day Three 
consisted o f the anaerobic treadmill test, and the dispensing of pills (Mg^* supplement or 
placebo) (Tl and T3 only), as well as training logs (T l, T2, and T3 only).
3.2.4 Treatment
In a double-blind manner, subjects were randomly assigned to begin treatment with 
either 212 mg/day (two pills of 106 mg elemental Mg^") Mg oxide (C.E. Jamieson and Company 
Ltd., Windsor, Ontario) (Group M/P) or matching placebo (Group P/M). Both the Mg^* 
supplement and the placebo were in tablet form, and were identical in appearance, consistency, 
and taste. The placebo contained 222 mg dicalcium phosphate, 12 mg purified stearic acid, 6  mg 
coscarmellose sodium, 4 mg silicon dioxide, and 276 mg microcrystalline cellulose. Subjects 
were instructed to consume the contents o f one tablet twice per day (one just before breakfast 
and one just before dinner). The treatment lasted four weeks (28 ±  3 days) which was followed 
by a 6 -week (42 ±  3 days) washout period. Treatments were then reversed for the final four 
weeks.
3.2.5 Training Diary
A total o f 11 subjective and 4 objective variables were recorded daily by the subjects in a 
standardized diary (refer to Appendix D). The variables were as follows; (1 ) length of training 
workout(s), (2) length of intensity section of workout(s), (3) morning rest pulse, (4) morning
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body weight, (5) energy, (6 ) quality of sleep, (7) training or competing willingness, (8 ) appetite,
(9) irritability, (10) muscle soreness, (11) minor illnesses, (12) minor injuries, (13) GI 
difficulties, (14) menstrual difficulties, and (15) stressful events. Of these, the first two and last 
five variables were used as control measures whereas the others were dependent (objective or 
subjective) measures of recovery.
3.3 EXPERIMENTAL DESIGN
A randomized, double-blind, crossover (Mg oxide vs. placebo) design was employed. 
Testing (identical to that noted above) occurred every four weeks (at T l, T2, T3 and T4). Figure 
1 shows the 14-week experimental design including the treatment and washout periods for each 
group. Subjects were grouped according to both treatment and Mg^* status. There were two 
treatment groups, one for which the order of pill administration was Mg^" supplement first and 
placebo second (group M/P), and the other, vice versa (group P/M). As for Mg^' status, subjects 
were re-classified (from the screening results) into three pools exhibiting either low, medium, or 
high [iMg] levels. (The reasoning for this is explained in the results section.)
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Figure 1. Experimental Design
WEEK# 0 4 1 0 14




High iMg (n=4) 
Medium iMg (n=4) 
Low iMg (n=5)






High iMg (n=8 ) 
Medium iMg (n=6 ) 
Low iMg (n=5)
Placebo [Washout] 2 1 2  mg 
Mg oxide
Note. Group M/P = Mg^'-treated first placebo-treatec 
Mg^*-treated second.
second; group P/M = placebo-treated first.
3.4 DEPENDENT VARIABLES
( 1) VOzmax (ml/kg/min)
(2) Maximal workload (% grade)
(3) Vgpeak (L/min)
(4) Workload at anaerobic threshold (mph)
(5) VOz at anaerobic threshold (ml/kg/min)
(6 ) Anaerobic treadmill test - time to exhaustion (s)
(7) Systolic blood pressure (mmHg)
(8 ) Diastolic blood pressure (mmHg)
[Remaining measures were performed five times, i.e., pre, 4, 10,30 min, and 24 hr post- 
incremental treadmill test]
(9) [iMg] (mmol/L) X 5
(10) [plasma lactate] (mmol/L) X 5
(11) [plasma glucose] (mg/dl) X 5
(12)[Hb](g/dl)X5
(13)H ct(% )X 5
(14) [iCa] (mmol/L) X 5
(15) [Na+] (mmol/L) X 5
(16) [K+] (mmol/L) X 5
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3.5 DATA ANALYSES
Data analyses were performed utilizing the statistical software o f STATISTICA™ ©1995 
(StatSoft, Inc., Tulsa, OK). Correlational coefficients were used to establish relationships 
between the baseline measures o f dietary intakes, hematological assays and performance 
variables. The dietary intakes and training diaries were examined so that any discrepancies in 
routine would be taken into account. In order to test if  a  carryover effect was present (i.e., if the 
washout period was ineffective) an independent t-test was performed on the [iMg] change scores 
from pre to post-treatment (Armitage and Hills, 1982). Once the carry-over effect was 
disclaimed (see results section), the data were pooled to test for differences between groups 
based on treatment (Mg^~ or placebo) and/or iMg status (high, medium and low). The differences 
between treatments were measured using Student’s t-test for paired samples (see also Dragani et 
al., 1995) on change scores from baseline values to treated values.^ The differences between 
status groups were measured using repeated measures analyses of variance (ANOVA).^ The 
accepted level o f significance was p < .05 for all statistical tests. Since the analyses did not 
reveal any differences between groups based on Mg^' status (see results section), results 
concentrate on the treatment effects.
^Alternative analyses in the form of mixed factorial ANOVAs on nonpooled data were 
also performed. Appendix H displays these chronological changes over the study.
^Alternative analyses in the form of mixed factorial ANOVAs on nonpooled data were 
also performed.
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CHAPTER FOUR: RESULTS
4.1 DESCRIPTION OF SUBJECTS
The characteristics o f the 121 subjects screened for the study are listed in Table 2. O f the 
121 originally screened for this study, 44 (or 36.4%) were marginally Mg^'-deficient according 
the criteria set by Altura, Shirey et al. (1994), i.e., they exhibited an [iMg] of less than 0.53 
mmol/L. Most subjects maintained their training regimes throughout the study, although there 
was some seasonal fluctuation, especially as several did not exercise consistently during the 
washout period which took place over the Christmas season. However, no differences in 
training, lifestyle, or dietary intake were apparent between treatment groups. Subjects 
participated in sporting activities which were aerobic (most often running, cross-country skiing 
and swimming) and/or anaerobic (most often weight training, soccer, basketball and volleyball). 
All participants possessed regular menstrual patterns and no gastrointestinal distress throughout.
The study was originally plarmed so that a group of marginally Mg^'-deficient individuals 
would be compared to a group with adequate stores of the mineral, as determined from 
screening results. Yet, since for some subjects, [iMg] levels had changed over the 3-week 
interval between the initial screening and the start of the main study (T l), and the Tl results 
showed a normal distribution, three groups were formed according to [iMg] level; low (below 
0.53 mmol/L) (n = 10), medium (0.53 to 0.58 mmol/L) (n = 10), and high (above 0.58 mmol/L)
(n = 12). As mentioned in the methods section, since there were no differences found between 
groups based on Mg^" status, results focus on the treatment effects.
Before completing the study, seven subjects dropped out from group M/P (n = 13 as a 
result), and one dropped out from group P/M (n = 19 as a result). O f these eight individuals, two
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became injured, three became ill, and three experienced scheduling difficulties; none were 
included in the analyses. Other data for various parameters were discarded in the case of a 
temporary equipment failure or subject noncompliance for a particular test.
Table 3 lists the characteristics o f  the 32 subjects completing the entire study as well as 
the characteristics of both treatment groups, M/P and P/M, with independent t-tests performed 
between groups. Since there were no significant differences between treatment groups on 
baseline measures, further analyses were justified. The mean dietary Mg^* intakes were 320 +
123 mg/day at T l and 333 ±  127 mg/day at T2. Each o f the two sets of dietary analyses revealed 
that six (or 20%) had intakes less than the RNI amount of 200 mg of Mg^*, and the same number 
had less than the 70% RDA amoimf*. Complete dietary intake data may be found in Appendix F. 
There was no correlation between Mg^~ intake and [iMg] at Tl (r = -.27).
4.2 TEST FOR CARRY-OVER EFFECT
In studies with crossover designs such as in this study, it is necessary to test for a carry­
over effect, i.e., to see if the supplemental Mg^* (or the placebo) still carried any effect from the 
first treatment period to the second treatment period (Armitage and Berry, 1987). Armitage and 
Hills (1982) also refer to this effect as the ‘treatment by period’ interaction, where ‘treatment’ is 
the factor representing the Mg^' supplementation or placebo, and ‘period’ is the factor 
representing the two periods of treatment. An independent t-test was performed between 
treatment groups on [iMg] change scores from pre to post-treatment (t̂ o> ̂  -0.05, p  > .05). The
Values over 70% of the RDA amount are in the acceptable range for adequate nutrition 
(Lukaski, 1995a).
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Table 2. Characteristics o f screened subjects
PARAMETER Means ± SD Range
Age(yrs) 21.5 + 4.2 17 -43
Height (cm) 165.8 + 6.2 151.5 - 178.0
Weight (kg) 63.2 + 8.2 45.0 -87.0
Resting [iMg] Level (mmoi/L) 0.538 + 0.040 0.46 -0.69
Systolic Blood Pressure (mmHg) 109.9 + 8.8 94 - 130
Diastolic Blood Pressure (mmHg) 66.8 + 7.9 50 -90
Note. (121 subjects)
Table 3. Baseline characteristics o f subjects completing entire study
PARAMETER All Subjects Group M/P Group P/M T-test Result
Age(yrs) 21.2 + 3.1 20.8+1.8 21.4 + 3.8 t(30) = -0.46
Height (cm) 165.5 + 5.6 166.3 + 7.2 165.0 + 4.2 t(30)= 0.63
Weight (kg) 61.5 + 5.3 61.9 + 7.1 61.2 + 3.8 t(30)= 0.34
Predicted Percent Body Fat (%) 22.5 + 4.0 23.1 +4.4 22.1 +3.8 t(30)= 0.70
Resting [iMg] Level (mmol/L) 0.567 + 0.032 0.560 + 0.037 0.572 + 0.029 t(30) = -1.04
Mgr* Intake (mg/day) 320.4+123.2 305.8 ±133.5 325.6+115.0 1(30) = -0.45
VOjmax (ml/kg/min) 49.8 + 6.3 49.4 + 6.8 50.2 + 6.1 1(30) = -0.34
Vgpeak (L/min) 109.2+12.3 109.3 + 11.1 109.2+13.3 1(30)= 0.04
Maximum Heart Rate (beats per min) 195.1 +9.5 200.0 + 7.2 193.9 + 9.5 1(30)= 1.96
VO, at Anaerobic Threshold (ml/kg/min) 37.4 + 4.6 38.3 + 4.9 36.7 + 4.4 1(30)= 0.94
Anaerobic Treadmill Test Result (s) 41.7+14.3 41.0+16.8 42.2+12.8 1(26) = -0.24
Systolic Blood Pressure (mmHg) 114.3 + 8.9 116.3 + 9.9 113.0 + 8.1 1(30)= 1.04
Diastolic Blood Pressure (mmHg) 69.4 ±  9.5 70.2+12.4 69.0 + 7.3 1(30)= 0.35
Note. Group M/P = Magnesium-1st, Placebo-2nd (n 
Magnesium-2nd (n = 19). Total o f 32 subjects or 30 
tests performed on treatment groups; *p< 05.
= 13); Group P/M = Placebo-1st,
for Mg^* intake; means ± SD. Independent t-
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test did not provide evidence of a treatment by period interaction, thus, data from the two 
treatment periods could then be pooled (or combined) to form two categories - Mg^'-treated (M), 
and placebo-treated (P).
4.3 MAGNESIUM STATUS
In the 3-week interval between the initial screening o f potential subjects and T l, resting 
[iMg] significantly increased from 0.532 ±  0.046 mmol/L to 0.567 ±  0.032 mmol/L, 1 3̂,, = 4.70; p 
< .05 (n=32). Only 15.6% were marginally deficient at T l. The correlation for resting [iMg] 
levels between screening and Tl was r = .45. Correlations between resting [iMg] levels from 
pre-treadmill test to 24-hr post-test were r = .55 (Tl), r = .35 (T2), r = .80 (T3), and r = .59 (T4). 
Pooled data revealed that throughout treatment the increase in resting [iMg] was significantly 
more for M (+0.044 mmol/L) vs. P (+0.028 mmol/L), = 2.28; p  < .05 (see also Table 4).^
4.4 PERFORMANCE AND RECOVERY
For this section, the reader is, again, referred to Table 4 (or Appendix G for blood 
indices) for pooled raw data and change scores, and t-tests on the change scores. Values for 
performance and recovery indices did not differ significantly between treatments. However, a 
trend was indicated for V^peak values in that they increased slightly more throughout treatment 
for M (+2.25 L/min) vs. P (-2.01 L/min), t<25) = 1.75; p = .09.®
®The change in [iMg] values over the natural progression o f the study is displayed in 
Appendix H utilizing nonpooled data.
®The changes in values for Vgpeak, VOgmax, and systolic blood pressure over the natural 
progression o f the study are displayed in Appendix H utilizing nonpooled data.
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Results indicated that four weeks o f treatment with 212 mg/day Mg oxide was successful 
in raising resting [iMg] levels. Previous research has discovered slight but insignificant increases 
in [TMg] and [EMg] (after three weeks of supplementation with 387 mg/day Mg pidolate) 
(Vecchiet et al., 1995). It may be that the [iMg] measure is more sensitive than [TMg] or [EMg] 
as previously claimed (Altura, 1994; Altura, Burack et al., 1994). Therefore, the use of this assay 
to assess the effects of Mg^' treatment on performance and recovery may be advantageous over 
other hematological measures of Mg^".
The significant increase in [iMg] levels from screening to Tl may be due to the subjects’ 
increased awareness and interest about their nutritional habits from their involvement in such a 
study. Since there were mostly weak correlations between resting [iMg] values, it seems that 
these levels were fairly labile within individuals. The instrument itself does not appear to 
account for this as the precision (coefficient of variation) of the ion-selective electrode for Mg^* 
has been reported to be excellent, i.e., less than 6 % for control samples (Altura, Shirey et al., 
1994), and indeed quality control samples and repeated sampling on the same blood yielded 
consistent values in the present study. The variability of [iMg] prevented effective analyses 
regarding the effects o f Mg^" status since subjects could not be consistently classified in the 
same status group throughout the study. The concept of natural regression toward the mean 
(Howell, 1987) may have also influenced the analyses as noted by the changes in [iMg] from 
screening to T l. The variability of [iMg] within individuals over time must be researched in 
more detail as the assessment, classification and diagnosis of Mg^^ status based on these values
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are put in jeopardy. Moreover, the ratio o f [iMg]/[TMg] has been reported to be consistent 
within individuals but not so between individuals (Altura, Shirey et al.); adding the [TMg] assay 
would thus further confirm the precision of the [iMg] measure. It would also be helpful to see 
whether the [iMg]/[TMg] ratio would be elevated (indicating increased mobilization o f Mg^*) in 
certain individuals. This method may add critical information about the existence o f deficiencies 
in the subject pool (H.C. Lukaski, personal communication, October 7, 1997).
The mean dietary Mg^" intakes o f 320 ±  123 mg/day (for T l) and 333 ±  127 mg/day (for 
T2) are well above both the RNI o f200 mg/day and the RDA o f 280 mg/day. Altura (1994) 
claimed that females (without regard to activity level) ingest approximately 175-225 mg/day 
Mg^" (60-80% of the RDA), while Lukaski (1995a) noted that female athletes take in about 168 - 
182 mg/day of the mineral (60-65% of the RDA). It seems that participants in this study possess 
Mg^" intakes which are higher than normal. Apart from being regular exercisers between the 
ages o f 17 and 29, the subjects appeared to be quite diverse in regards to dietary habits. Some 
subjects gave conscientious effort to obtaining a healthy diet whereas others tended toward 
highly refined convenience foods that often lack Mg^" in adequate amounts. In addition, since 
there was no correlation between Mg^" intakes and [iMg] levels (r = -.27), it may be that there is 
a wide variability in the way in which Mg^" is metabolized. This may have meant that the 
supplementation would have had less effect on some participants.
5.2 PERFORMANCE AND RECOVERY
There were no significant effects o f Mg^* supplementation on performance during (or 
recovery from) aerobic or anaerobic exercise. Previous studies have discovered benefits o f Mg^*
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treatment on VOjmax (Steinacker et al., 1987), total workload (Vecchiet et al., 1995), and time 
to exhaustion (Brilla and Gunter, 1995). Magnesium treatment has also been shown to improve 
submaximal performance by decreasing submaximal VO ,̂ V^, and HR (Brilla and Gunter; Ripari 
et al., 1989). Yet all o f  these studies involved higher dosages o f Mg^~ supplementation and either 
reported subjects with lower mean Mg^* intakes or did not report intakes at all. Moreover, only 
Vecchiet and colleagues incorporated the highly controlled crossover experimental design as 
utilized in this study. These choices may have contributed extensively to reporting significant 
effects. In addition, it is difficult to speculate on the possibility o f Mg^' deficiencies in the 
research of Brilla and Gunter as well as that o f Ripari and co workers since Mg^* status was not 
assessed. The results o f the present study are more in line with those of Weight, Noakes et al. 
(1988). These investigators utilized a crossover design and a lower dose of Mg^* (116 mg/day) 
and found no significant effects on performance in subjects with high Mg^' intakes (372 ±  122 
mg/day).
On the other hand, it is possible that the present study is lacking in certain areas which 
may have been critical for obtaining positive effects of Mg^* supplementation; this is now 
discussed. The relatively high mean Mgf" intake of the participants and the relatively low dosage 
of Mg^~ supplementation may have prevented the opportunity for significant increases in 
absorption of the mineral in the body. Although this study built on previous research in the area 
by utilizing the sensitive [iMg] measure to assess Mg^' status, the discovery that [iMg] appears 
to be rather labile compromises its usefulness (at least until further research can elucidate all of 
the physiological factors contributing to the variability). As well, since reference ranges for 
[iMg] levels have not yet been well-established, it is difficult to confirm whether some subjects
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were initially Mg^'-deficient or not It is still hypothesized that if those initially marginally Mg^*- 
deficient had normal and controlled dietary intakes, they would benefit from supplementation 
with possibly a higher dosage of Mg^*.
5.3 CONCLUSIONS AND SUGGESTIONS FOR FURTHER RESEARCH
This study concluded that four weeks of 212 mg/day Mg oxide supplementation 
significantly improved resting [iMg] levels but not performance or recovery in a group of 
physically active females. The conclusions appear to hold true regardless o f initial iMg status 
(normal or marginally-deficient). Possible reasons for which the present study did not note a 
significant improvement in performance and recovery from exercise are as follows: Dietary 
intakes were higher than normal, the Mg^' dosage ( 2 1 2  mg/day) may have been too low, and 
[iMg] levels were shown to be quite labile proving it difficult to diagnose deficiencies of the 
mineral. It may also be that the supplementation would have had less effect on some participants 
due to the wide variability in the way in which Mg^' is metabolized. However, it appears that the 
[iMg] measure is more sensitive than [TMg] or [EMg] warranting the use of this assay to assess 
the effects o f Mgf' treatment in athletic situations.
This study was unique in utilizing the [iMg] assay in testing physically active females on 
exercise performance and recovery. A major recommendation for further research is to conduct 
repeated [iMg] assays within individuals to elucidate the degree of variability in [iMg] and to 
determine the causes of it. In addition, reference ranges for [iMg] must be described in more 
detail. Future studies similar to this should incorporate additional indices of Mg^* status, indices 
of muscle damage, controlled diet and training regimes, more frequent dietary assessments.
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different doses of Mg^', and blood sampling during treadmill testing. Also, an extra group may 
be added for control to which no treatments are given.
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Please fill out the following questions as completely and accurately as possible.
1. Record the number of hours you spend exercising in an average week (7 days). Any exercising 
is applicable if  it is performed at least a moderate (65% of maximum) intensity. Do not include 
stretching or lightly warming up or cooling down. If your weekly value varies during the year, 
record the suspected amount of hours that you would exercise during this study (autumn and 
winter of 1996).
2. Record the number of sessions you spend exercising in an average week (as above).
3. List each sport or type of exercise you are presently involved in plus the number of years you 
have been participating in each.
4. Name all vitamin and/or mineral supplements you are presently taking. (Include brand names, 
names of vitamins and minerals, and quantities of each, if known.)
5. List all medications and oral contraceptives taken presently.
6 . Have you had a history of menstrual difficulties (i.e., if menses are in excess or in absentia)?
7. List all known food allergies that you have.
8 . List all known medical conditions that you have had in your lifetime (including alcoholism, 
diabetes, etc.).




I ,__________________ (please print name), hereby consent to participate in this research study
involving magnesium supplementation and its effect on exercise performance and recovery.
The purpose and procedures involved have been thoroughly explained to me. I will do my best 
in maintaining a consistent routine with respect to diet and training. I will not take any extra 
magnesium supplements for 4 weeks prior to the study as well as during the study. 1 will take 2 
capsules o f a supplement or placebo daily for 28 days at a time. 1 realize that at any, time, and 
for any reason, I can withdraw from the study.
Any risks involved in this study have been explained to me. The treatment dosage o f 
magnesium (200 mg/day) is the Canadian Recommended intake and should pose no negative 
side effects. Blood sampling will be conducted by a phlebotomist. The amount o f blood drawn 
will be small and there will be little discomfort with the procedure. There may be slight 
bruising and/or tenderness at the point of puncture. The treadmill tests involve maximal effort 
and thus the discomfort associated with temporary exhaustion will be felt. In healthy 
individuals this type o f exercise carries no risk.
The data derived from individual subjects will remain confidential and publication of the 
results will not reveal subject identity as the subjects will be referenced by number. Upon the 
completion of the study, all subjects will be briefed on their individual results and, upon 
request, receive a summary of the project.
Signature of participant Date




Please read carefully over all of the following instructions and ask the experimenters if any 
clarifications are needed. Before going any further, you will not be able to participate in this 
study if:
1 ) you are pregnant, and/ or
2) you have had any clinical history of proven or suspected hypersensitivity to Mg 
supplements (e.g., diarrhea), and/ or
3) you will be leaving the Thunder Bay area before the end of this study (which may 
extend into January or February, 1997).
1. Sign the consent form and fill out the questionnaire.
THE FOLLOWING ONLY APPLY TO THE RESULTANT 40 SUBJECTS:
2. Refrain from unaccustomed strenuous exercise for 48 hours and any strenuous exercise for 
24 hours (and alcohol or caffeine products for 6  hours) prior to each treadmill test. Fill out a 
PAR-Q questionnaire for fitness testing upon arrival.
3. Consume a light carbohydrate rneal (e.g., cereal and milk, and/or toast and/or fruit) about 2 
to 3 hours prior to each treadmill test.
4. Fifty-six tablets will be given to you at the end of the first testing session as well as the third. 
The supplements are to be taken during each subsequent 4 week period. During these periods, 
ingest two tablets daily, one just before breakfast, and one just before dinner. No supplements 
are to be taken during the period in between the second and third testing sessions.
5. Leave the training log beside your bed so that you can fill out the first part of it in the 
morning upon awakening and the other part in the evening before retiring.
A) In order to get an accurate resting heart rate, lay down 5 minutes and then take pulse 
at wrist or neck and count the number of beats in 30 seconds. Multiply by 2 to get beats 
per minute.
B) Measure morning body weight (unclothed) before any food intake or excretion. Note 
if it is measured in kilograms or pounds and round off to the nearest half-kilogram or to 
the nearest pound. Use the same scale each day.
C) To record the number of minutes spent exercising, do not include the time spent 
stretching or lightly warming up or cooling down.
D) To record the number of minutes in the intensity section of exercise, the effort 
exerted during these sessions should prevent you from carrying on a normal
conversation.
6 . Keep exercise and dietary habits consistent throughout the study period. Report any major 
changes in these habits in the daily diary.
7. To make, confirm, or cancel your appointments for testing, or to ask any questions regarding 
the study, please call Eric at 343-8187 (graduate student office) or at 345-7025 (home). Please 
leave a message if 1 am not available.




The information we can produce for you is only as accurate as the information you provide. 
Please, therefore, follow these instructions to the letter We will analyze 3 days. Two of 
these days will be weekdays and one day will be on a weekend (e.g., a Thursday, Friday and 
Saturday). Try to consume the amount and types o f foods and drinks you would normally 
consume. Try to record the amounts as accurately as possible, i.e., weighing with a scale, 
using a measuring cup, using relative size (e.g., med. banana), and reporting each ingredient if 
item content is vague (e.g., 10 inch pizza with green peppers, olives and pepperoni). Also 
report, for example, if bread is white or whole wheat, milk is skim or whole, etc. Use back of 
page if needed.
Name:___________________________
Date/ day/ time Amount Brand Name Food or Drink Item




Group (A or B):. 
Name:________
Session (1st, 2nd or 3rd):_____
Start and finish dates of session:
* Please fill out this training log as completely and accurately as possible.
* For questions with multiple choices (e.g., #3), shade in the most appropriate box.
* For questions with scales, normal = with respect to only yourself.
* For questions # 4, 12, 13, 14 & 15, shade In the box for any day that symptoms are occurring.
* Fill out first 4 questions (just this page) every morning upon awakening.
1. Vloming resting heart rate l)eats per minute) Multip y 30 second count by 2)
d 1 2 3 4 5 6 7 8 9 1 1 1 1 1 1 1 1 1 1 2 2 2 2 2 2 2 2 2
y 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8
X
2. Moming body weight (Indicate if in 1 3 . or kg) (IRecord to nearest lb. or neares half-kg)
d I 2 3 4 5 6 7 8 9 1 1 1 1 1 1 1 1 1 1 2 2 2 2 2 2 2 2 2
y 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8
X
3. Quality of sleep (I = very, very low; 2  = very low; 3 = low; 4 = normal; 5 = high; 6  == very
high; 7 = very, very high)
d 1 2 3 4 5 6 7 8 9 1 1 1 1 1 1 1 1 1 1 2 2 2 2 2 2 2 2 2








4. Minor i Inesses (e.g..cold, f u)
d 1 2 3 4 5 6 7 8 9 1 1 1 1 1 1 1 1 1 I 2 2 2 2 2 2 2 2 2
y 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8
X
Comments regarding above (i.e., illness types and symptoms experienced)
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* Fill out the remaining questions every evening just before retiring to bed 











































6. Length of intensity section of exercise session(s) (minutes)
d 1 2 3 4 5 6 7 8 9 1 1 1 1 1 1 1 1 1 1 2 2 2 2 2 2 2 2 2
y 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8
X
7. General energy level ( I = very, very low; 2 == very low, 3 = low, 4 = normal; 5 = high;
6 == very ^igh; 7 = very, very hig h)
d 1 2 3 4 5 6 7 8 9 1 1 1 1 1 1 1 1 1 1 2 2 2 2 2 2 2 2 2








8. Training or competition willingness (I = very, very low; 2 = very low; 5 = low; 4 = normal;
5 == hi 6 = very high; 7 = very , veryhigh)
d 1 2 3 4 5 6 7 8 9 1 1 1 1 1 1 1 1 1 1 2 2 2 2 2 2 2 2 23
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10. Irritability level (1 == very, very low; 2  = very low; 3 == low; 4 = normal; 5 = high;
6  == very ligh; 7 = very, very trig I)
d 1 2 3 4 5 6 7 8 9 1 1 1 1 1 1 1 1 1 1 2 2 2 2 2 2 2 2 2








11. Level o f muscle soreness ( 1 = very, very much; 2 = very much; 3 = much ; 4 = normal;
5 == little ; 6 = very litt e ; '/ = very, very little)
d 1 2 3 4 5 6 7 8 9 1 1 1 1 1 1 1 1 1 1 2 2 2 2 2 2 2 2 2
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2 . Minor injuries (e.g. shin splints)
d 1 2 3 4 5 6 7 8 9 1 1 1 1 I 1 1 1 1 1 2 2 2 2 2 2 2 2 2
y 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8
X
Comments regarding above (i.e., injury types)
3. Gastrointestinal difficulties
d 1 2 3 4 5 6 7 8 9 1 1 1 1 1 1 1 1 1 1 2 2 2 2 2 2 2 2 2
y 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8
X
Comments regarding above (e.g., diarrhea)
14. Menstrua tion
d 1 2 3 4 5 6 7 8 9 1 1 1 1 1 1 1 1 1 1 2 2 2 2 2 2 2 2 2
y 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8
X
Comments regarding above (e.g., excessive)
Vtoor stressful events
d 1 2 3 4 5 6 7 8 9 1 1 1 I I I 1 I I 1 2 2 2 2 2 2 2 2 2
y 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8
X
Comments regarding above (e.g., exams, job and family troubles)
16. Additional Comments (e.g., major changes in sleep or dietary routine)
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Appendix F
DAILY DIETARY CHARACTERISTICS OF PARTICIPANTS
DIETARY
PARAMETER T l T3
FEMALE (19-24) NEEDS 
RNI (CAN) RDA (US)
Energy (kcal) 2196 ±765 2145 ±791 — —
Carbohydrates (g) 328+ 124 319±110 289 275
Proteins (g) 70.5 + 29.7 73.7 ±25.8 43 46
Fats (g) 65.8 + 35.2 66.9 ±44.3 70 73
% Carbohydrate 59.8 + 9.8 59.4 ±10.5 72 70
% Protein 12.8 + 2.5 13.8 ±2.6 11 1 2
% Fat 26.3 ±8.1 26.2 ±9.7 17 18
Fibre (g) 22.7 ±9.9 22.4 ±9.7 — —
Cholesterol (mg) 189 ±158 183 ±152 — 300
Magnesium (mg) 320 ± 123 333 ±127 2 0 0 280
Calcium (mg) 994 ±  352 1029 ±434 700 1 2 0 0
Sodium (mg) 2953± 1190 2796 ±1170 — 500
Potassium (mg) 3211± 1756 3615 ±1567 — 2 0 0 0
Iron (mg) 16.0 ±6.3 17.1 ± 8 . 8 13 15
Zinc (mg) 9.27 ±3.50 9.64 ±3.72 — —
Phosphorus (mg) 1261 ±365 1327 ±486 850 1 2 0 0
Vitamin A (RE) 1635± 1532 1726 ±930 800 800
Thiamin-Bl (mg) 1.99 ±1.05 2.40 ±1.28 0 . 8 1 .1
Riboflavin-B2 (mg) 2.19 ±0.98 2.33 ±0.96 1 .1 1.3
Niacin-B3 (mg) 19.2 ±6.9 24.0 ±  10.4 15.0 15.0
Vitamin B6  (mg) 1.75 ±0.73 2.22 ±0.96 — 1 .6
Vitamin B12 2.81 ±  1.53 3.50 ± 1.82 2 . 0 2 . 0
Vitamin C (mg) 217 ±352 268 ±236 30 60
Vitamin D (//g) 4.23 ±2.18 5.85 ±4.10 — —
Vitamin E (mg) 6.92 ±4.99 5.47 ±3.07 — —
Note. (30 subjects); means ± SD
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Appendix G
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+7.31 K27) = 0.29
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+0.74 K27) = 0.56











+4.47 1(25) = 0.26












Note. Pooled data based on treatment: M = Magnesium; P = Placebo. Baseline and Treated, 
tests performed before and after treatment, respectively (means ±  SD). Student’s t-tests 
performed on change scores; *p<.05.
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Appendix G (Continued)
HEMATOLOGICAL INDICES BY TREATMENT
PHYSIOLOGICAL TREAT- 
VARIABLE MENT
RAW SCORES CHANGE T-TEST
Baseline Treated Actual % RESULT
Resting Ca** M
(mmol/L) P
4 min post-test Car' M
(mmol/L) F
10 min post-test Ca*' M
(mmol/L) P
30 min post-test Car~ M
(mmol/L) P




4 min post-test Na' M
(mmol/L) P
10 min post-test Na' M
(mmol/L) P
30 min post-test Na' M
(mmol/L) P




4 min post-test K' M
(mmol/L) P
10 min post-test K' M
(mmol/L) P
30 min post-test K' M
(mmol/L) P
















144 ± 1.8 
144±1.8
144 ± 1.6 
144± 1.5
















144 ± 1.4 
144±1.9




4.26 ±0.39 4.34 ±0.32
4.24 ± 0.29 4.27 ±0.30
4.08 ±0.30 4.15 ±0.26
3.99 ±0.25 4.11 ±0.22
4.12 ±0.31 4.23 ±0.30
4.09 ±0.27 4.20 ±0.23
4.37 ± 0.28 4.49 ± 0.33
4.27 ± 0.29 4.47 ±0.33
4.33 ±0.33 4.45 ±0.33





































t(27) = -1.29 
t(29) = 0.36 
1(30) = 0.84 
1(30) = 1.22 
1(27) = 0.30 
1(27) =-0.46 
1(28) = 0.69 
K30)=-0.66 
1(30) = -0.04 
1(27) = -0.67 
1(27) = -0.21
Note. Pooled data based on treatment; M = Magnesium; P = Placebo. Baseline and Treated, 
tests performed before and after treatment, respectively (means ±  SD). Student’s t-tests 
performed on change scores; *p<.05.
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Appendix G (Continued)
HEMATOLOGICAL INDICES BY TREATMENT
PHYSIOLOGICAL TREAT­ RAW SCORES CHANGE T-TEST
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+0.70 K30) = -0.67











+0.58 K30) = -0.40











+0.66 K27) = 0.35











+0.51 K25) = -0.14











- 1.42 K31) = -1.26











-0.36 K31) = -0.36
Note. Pooled data based on treatment: M = Magnesium; P = Placebo. Baseline and Treated, 
tests performed before and after treatment, respectively (means ±  SD). Student’s t-tests 
performed on change scores; *p<.05.
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Figure 1. Resting [iMg]; Mixed factorial ANOVA: F = 1.82, p  > .05
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Figure 2. Peak ventilation: Mixed factorial ANOVA: F 3̂ 72) = 2.51, p  > .05
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Appendix H (Continued)
ANALYSES OF VARIANCE FOR NONPOOLED DATA
Figure 3. Maximum volume of oxygen uptake: Mixed factorial ANOVA: F ^3 75) = 1.89, g > .05
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Figure 4. Resting systolic blood pressure: Mixed factorial ANOVA: FE 0 .72) = 2.51, g  > .05
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